Clinical Trials Logo

Leukemia, Myeloid clinical trials

View clinical trials related to Leukemia, Myeloid.

Filter by:

NCT ID: NCT04360005 Available - Clinical trials for Chronic Myeloid Leukemia in Chronic Phase

Managed Access Programs for ABL001, Asciminib

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this registration form is to list all Managed Access Programs (MAPs) related to ABL001, asciminib

NCT ID: NCT04354025 Withdrawn - Clinical trials for Refractory Acute Myeloid Leukemia

Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AML

Start date: June 30, 2023
Phase: Phase 2
Study type: Interventional

This phase 2 clinical trial investigates the effectiveness of cytokine-induced memory-like natural killer (CIML NK) cells in combination with FLAG chemotherapy as a treatment for refractory or relapsed AML. Previous studies in adults with AML sowed successful induction of remission and a previous phase 1 study demonstrated that CIML NK cells can be used safely in pediatric patients. This phase 2 study uses FLAG chemotherapy to lower leukemic burden and suppress the recipient's immune system to provide an optimal environment for CIML NK cell expansion and anti-leukemic activity.

NCT ID: NCT04353479 Not yet recruiting - Clinical trials for Acute Myeloid Leukemia

Combined PD1 Inhibitor and Decitabine in Elderly Patients With Relapse and Refractory Acute Myeloid Leukemia

Start date: April 25, 2020
Phase: Phase 2
Study type: Interventional

This is an open-label, single arm, phase 2 study to evaluate efficacy and safety of PD1 inhibitor Camrelizumab(SHR-1210) combined with DNA methyltransferase inhibitor decitabine in elderly patients with relapse and refractory acute myeloid leukemia.

NCT ID: NCT04351022 Recruiting - Clinical trials for Acute Myeloid Leukemia

CD38-targeted Chimeric Antigen Receptor T Cell (CART) in Relapesd or Refractory Acute Myeloid Leukemia

Start date: July 1, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This is a single center, open-label phase 1/2 study to evaluate the safety and efficacy of targeted CD38 chimeric antigen receptor engineered T cell immunotherapy (CART) in the treatment of CD38 positive relapsed or refractory acute myeloid leukemia.

NCT ID: NCT04347616 Recruiting - Clinical trials for Acute Myeloid Leukemia Refractory

Natural Killer-cell Therapy for Acute Myeloid Leukemia

NK4AML
Start date: December 3, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This study investigates an innovative treatment for relapsed or refractory acute myeloid leukemia exploiting administration of ex vivo-generated allogeneic natural killer (NK) cells with preceding non-myeloablative conditioning chemotherapy with or without subsequent in vivo IL-2 cytokine support.

NCT ID: NCT04342962 Recruiting - Clinical trials for Acute Myeloid Leukemia

Tagraxofusp in Patients With CD123+ or With BPDCN-IPh-like Acute Myeloid Leukemia

Start date: February 16, 2021
Phase: Phase 2
Study type: Interventional

Non-randomized, open-label, multicenter phase II Study for the treatment of - 25 R/R BPDCN-IF (CD123/CD4/CD56 positive) AML patients and - 25 patients presenting R/R AML CD123+, but negative for either, or both, CD4 and CD56. Patients will be treated with 12 mcg/kg/day of tagraxofusp for 5 days, for at least 4 cicles.

NCT ID: NCT04337138 Completed - Clinical trials for Leukemia, Myeloid, Acute

A Study Of Treatment Patterns And Clinical Outcomes In Patients Diagnosed With Acute Myeloid Leukemia Who Received Mylotarg in the Real-World

Start date: April 7, 2020
Phase:
Study type: Observational

The aim of this observational study is to describe treatment patterns and effectiveness outcomes in a sample of oncology patients treated for AML with Mylotarg through up to two additional relapsed/refractory (R/R)-based lines of therapy (through third-line therapy). The study will use United States oncology electronic medical record (EMR) data. All study data are secondary data and will have been collected retrospectively from existing clinical data originally collected as part of routine care.

NCT ID: NCT04336982 Terminated - Clinical trials for Leukemia, Myeloid, Acute

A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia

Start date: August 5, 2020
Phase: Phase 1
Study type: Interventional

CC-90009-AML-002 is an exploratory Phase 1b, open-label, multi-arm trial to evaluate the safety and efficacy of CC-90009 in combination with anti-leukemia agents in participants with acute myeloid leukemia (AML).

NCT ID: NCT04326439 Terminated - Clinical trials for Acute Myeloid Leukemia

AflacLL1901 (CHOA-AML)

Start date: January 24, 2020
Phase: Phase 2
Study type: Interventional

The investigators propose to study an Aflac-AML chemotherapy backbone prospectively to validate its use in all pediatric AML and to further evaluate the cardiotoxicity with this approach for low risk AML.

NCT ID: NCT04321161 Completed - Clinical trials for Acute Myeloid Leukemia, in Relapse

Analysis of T Cell Metabolism in Relapsed AML Patients With DLIs and Bicanorm Treatment

Start date: February 25, 2020
Phase: Early Phase 1
Study type: Interventional

In this study, the outcomes of relapsed AML patients receiving DLIs and Bicanorm (Sodium bicarbonate) were analyzed including T cell metabolism and immune phenotype.